Navigation Links
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
Date:12/1/2011

pleted.  Clinical investigators include Dr. Howard Burris at Sarah Cannon Research Institute, Dr. Roger Cohen at Hospital of the University of Pennsylvania/Abramson Cancer Center and Dr. Keith Flaherty at Massachusetts General Hospital.

About MGA271
MGA271 is a humanized IgG1/kappa monoclonal antibody that recognizes human B7-H3, a novel member of the B7 family of immune regulators.  B7-H3 is an attractive target for immunotherapy, as it is over-expressed in a variety of solid tumors, including prostate, pancreatic, renal cell, ovarian, colorectal, gastric, bladder, and non-small cell lung cancers as well as melanoma. MGA271 has been Fc-optimized using MacroGenics' proprietary Fc-engineering platform to further augment its tumor killing activity. The product's Fc region imparts increased affinity for the human activating Fc-gamma receptor IIIA (Fc-gamma RIIIA, CD16A) and decreased affinity for the inhibitory Fc-gamma RIIB (CD32B).

About MacroGenics
MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for cancer, autoimmune disorders and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a leading research capability for screening and targeting cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) bispecific technology, which allows the incorporation of multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions.  The company has global product development collaborations with Boehringer Ingelheim and Pfizer Inc. which employ its DART technology.  For more information about MacroGenics, ple
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
2. MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28
3. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
4. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
5. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
6. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
7. Intercept Pharmaceuticals and Servier Announce Agreement for Intercepts TGR5 Research Program in Type 2 Diabetes
8. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
9. Zimmer to Establish Asia-Pacific Research and Development Center
10. vRad Selected by Abbeville Area Medical Center for PACS Replacement
11. ETCs Aircrew Training Systems Completes Factory Acceptance Tests for Highly Advanced Suite of Training Equipment for the Republic of Korea Air Force Aeromedical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Today DePuy Synthes Companies ... angle plating systems featuring its proprietary variable angle ... screw trajectory to match patient anatomy and fracture ... bone. The systems are being introduced in conjunction ... (AOFAS) and the International Federation of Foot & ...
(Date:9/19/2014)... /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... report firstly reviews the basic information of ... manufacturing technology. The report then explores global ... listing their product specification, capacity, Production value, ...
(Date:9/19/2014)... 19, 2014 Research ... the addition of the "Global Gynecological ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... classified into wide categories based on their ... treatment of different gynecological conditions that affect ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
... March 5, 2012   Synteract , Inc., a full-service contract ... MBA, as senior vice president of sales and marketing and ... president, global project management, to support growth in the company ... Barr, COO Stewart Bieler, and CFO Patrik Jeanmonod on the ...
... Checkpoint Surgical has received the CE mark ... intraoperative neuroprotective stimulator that helps surgeons locate, identify ... to facilitate nerve preservation and repair. ... certification demonstrates that a medical device meets rigorous ...
Cached Medicine Technology:Synteract Expands Executive Roles to Support Growth 2Synteract Expands Executive Roles to Support Growth 3Checkpoint Surgical Receives CE Mark 2
(Date:9/21/2014)... Over the past five years, the patent ... market, thereby cutting into revenue growth for the ... from Industry Canada, the loss of patent protection for ... billion in 2010 and 2012, respectively. “In response to ... hampered revenue growth, many pharmaceutical manufacturers have streamlined their ...
(Date:9/21/2014)... metastasize? Think of Sparta. , Ancient Greek warriors were ... the demands of battle on distant fields. Cancer cells ... a new study revealing previously unknown differences between cancer ... site, and those that travel to other organs. , ... is the primary cause of cancer-related death, understanding how ...
(Date:9/21/2014)... 2014 Hundreds of Risperdal lawsuits ... Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard ... next monthly meeting has been scheduled for October ... “Our Firm is representing a number of plaintiffs ... We are pleased with its continued progress,” says ...
(Date:9/21/2014)... Cheap Hosting USA, one of the leading review websites, ... the best Reseller hosting suppliers in 2014. “It is ... these companies have outperformed their competitors on hosting features, ... the best web hosting at affordable rates,” the site’s ... reseller hosting is a very popular way for webmasters ...
(Date:9/21/2014)... Dallas, TX (PRWEB) September 21, 2014 ... and Chinese Fenofibrate (CAS 49562-28-9) Industry, 2009-2019 ... on Global and Chinese Fenofibrate (CAS 49562-28-9) ... information of Fenofibrate (CAS 49562-28-9) including its ... explores global and China’s top manufacturers of ...
Breaking Medicine News(10 mins):Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Cancer cells adapt energy needs to spread illness to other organs 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4
... According to the U.S. researchers, 80% accuracy in prediction of ... is achieved by a new test that examines the// genetic ... researchers at Duke University in North Carolina report that this ... only a single drug against a particular cancer but also ...
... studies offers good news and bad news for women faced ... ,The good news is that screening mammography does reduce ... mammograms are 15 percent less likely to die of breast ... ,The bad news is that women in a screened population ...
... are at increased risk of burnout, which seems ... depression, reports a study in the// October Journal ... the American College of Occupational and Environmental Medicine ... of the Finnish Institute of Occupational Health, Helsinki ...
... technical university preparing engineers and other professionals, female foeticide ... take up but the Punjab Technical University (PTU) is ... social issues. // ,The campaign by PTU gets ... and Technology (SVIET) at Banur, 25 km from here. ...
... has always been considered as a 'pleasure chemical,' in charge ... extols a person or animal for the continuous activity that ... certain drugs like cocaine and heroin can simply intensify this ... the University of Michigan adds a new twist to dopamine's ...
... Pharmaceuticals Corporation, Zaditor? (ketotifen fumarate ophthalmic solution 0.025%), ... due to allergic conjunctivitis has been endorsed by ... over-the-counter use. Eye allergies affect around 40 million ... to seasonal allergens like pollen and ragweed, or ...
Cached Medicine News:Health News:Genomic tests for better cancer treatment 2Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 2Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 3Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 4Health News:Burnout Explains Link Between Job Strain and Depression 2Health News:Zaditor? - over-the-counter drug for itchy eyes 2
... Design Holds The Lens Securely During ... Blades Keep The Optic From Being ... Over Release Of The Optic.,Wide Jaw ... During Insertion.,Reusable, Autoclaveable, Made In The ...
... Unique In-Line Footplates Are Turned 90 ... The Diamond Blade While Incising Tissue. ,Special ... Blade Depth Penetration.,Pre-Set Blade Extension Settings ... Retraction And Full Extension.,1mm Wide Snub ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Pocket-sized instrument with 2.5X magnification....
Medicine Products: